A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma by Sergiu Scobioala et al.
RESEARCH Open Access
A treatment planning study comparing
tomotherapy, volumetric modulated arc
therapy, Sliding Window and proton
therapy for low-risk prostate carcinoma
Sergiu Scobioala*, Christopher Kittel, Nicolas Wissmann, Uwe Haverkamp, Mohammed Channaoui, Omar Habibeh,
Khaled Elsayad and Hans Theodor Eich
Abstract
Background: Comparing radiation treatment plans to ascertain the optimal intensity-modulated radiation technique
for low-risk prostate cancer.
Methods: Treatment plans for 20 randomly selected patients were generated using the same dose objectives. A
dosimetric comparison was performed between various intensity-modulated techniques, including protons. All
treatment plans provided conventional treatment with 79.2Gy. Dosimetric indices for the target volume and organs at
risk (OAR), including homogeneity index and four conformity indices were analyzed.
Results: No statistically significant differences between techniques were observed for homogeneity values. Dose
distributions showed significant differences at low-to-medium doses. At doses above 50Gy all techniques revealed a
steep dose gradient outside the planning target volume (PTV). Protons demonstrated superior rectum sparing at
low-to-higher doses (V10-V70, P < .05) and bladder sparing at low-to-medium doses (V10–V30, P < .05). Helical
tomotherapy (HT) provided superior rectum sparing compared to Sliding Window (SW) and Rapid Arc (RA) (V10–
V70, P < .05). SW displayed superior bladder sparing compared to HT and RA (V10–V50, P < .05). Protons generated
significantly higher femoral heads exposure and HT had superior sparing of those.
Conclusion: All techniques are able to provide a homogeneous and highly conformal dose distribution. Protons
demonstrated superior sparing of the rectum and bladder at a wide dose spectrum. The radiation technique itself
as well as treatment planning algorithms result in different OAR sparing between HT, SW and RA, with superior
rectum sparing by HT and superior bladder sparing by SW. Radiation plans can be further optimized by individual
modification of dose objectives dependent on treatment plan strategy.
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Background
Different radiotherapy techniques and fractionation re-
gimes are currently used for the treatment of localized
prostate cancer. Conventionally fractionated intensity
modulated radiotherapy (IMRT) is the most frequently
applied treatment modality for prostate cancer [1–4].
IMRT can be performed either by static (“step-and-shoot”
(SS), Sliding Window (SW)) or rotational approaches
(helical tomotherapy (HT) or Volumetric Modulated
Arc Therapy (Rapid Arc, RA). Intensity modulated
proton therapy (IMPT) is also a well-known treatment
modality for localized prostate cancer and is more
likely to spare the organs at risk (OAR) due to steep
dose gradients outside of the Bragg peak [5–9]. All of
these techniques are capable of achieving treatment
plans with high conformity, reducing the dose deliv-
ered to the surrounding healthy tissue and, conse-
quently, treatment-related toxicities, especially the risk
of secondary malignancy. To date there is no consen-
sus on the “optimal overall” treatment mode [10, 11].
In this study, a statistical analysis of dosimetric param-
eters between HT, SW, RA and IMPT providing con-
ventionally fractionated radiotherapy was evaluated.
Similar dose objectives for PTV and OAR were used in
the radiation planning for all techniques. The dosimet-
ric indices were assessed according to the criteria of
the International Commission on Radiation Units and
Measurements (ICRU) Report 83 [12].
Material and methods
Treatment plans were generated for 20 randomly se-
lected patients with low-risk prostate cancer who re-
ceived definitive HT. The databases of thin-cut 3 mm
CT scans were fused with those of 1.5 T MRI scans. The
target dose was calculated to be 79.2Gy. According to
ICRU Report 83, at least 95 % of the prescribed dose
should cover 98 % of the prostate volume (D98 %) and a
maximum of 107 % of the prescribed dose should cover
2 % of the prostate volume (D2 %) [12]. Both dose objec-
tives for PTV and OAR, as well as multiple specific
physical planning support structures used for treatment
planning are presented in a “Additional file 1”. Seven-
field IMRT plans using the SW technique were created
on the Eclipse™ 10 treatment planning system [Varian
Medical Systems, Palo Alto USA]. All plans were gener-
ated for the Varian True Beam linear accelerator
(LINAC) using beam energies of 15MV photons and
beam angles of 0, 51, 102, 153, 204, 255 and 306°. The
RA plans were created using the same treatment plan-
ning system as for SW. Two incomplete arcs from 200
to 160°, intended to protect the posterior rectum wall,
were used. The plans were created using 15MV photons
with a 0.5 cm leaf width. A maximum dose rate of 600
MU/min and MLC motion of 2.5 cm/s were applied.
The MLC-leakage was at 1.8 %. The HT plans were
assessed using Tomo Planning System Version 5
(Accuray® Inc., Sunnyvale, USA). The plans were created
for the High Art HDII HT system that uses a helical slice
6MV photon beam modulated by 64 binary multileaf
collimators. The IMPT plans were generated using the
Eclipse™ 10 treatment planning system (Varian Medical
Systems, Palo Alto USA). Each plan consisted of two op-
posing right and left lateral beams (gantry angles of 90°
and 270°) with incident proton beam energies in the
100–235 MeV range. To create homogeneous target
coverage, a multi-field optimization was used with mini-
mum spot MUs of 0.4.
The clinical target volume (CTV) and planning target
volume (PTV) were defined according to the Radiation
Therapy Oncology Group (RTOG) 0521 protocol [13].
The CTV included the prostate and did not involve the
seminal vesicles. A 3 mm margin in the dorsal direction
and 5 mm margin in all other directions was added to
delineate the PTV. The dose-volume objectives met the
criteria for rectum and urinary bladder set out by the
Quantitative Analyses of Normal Tissue Effects in the
Clinic (QUANTEC) reports and for femoral heads estab-
lished by the RTOG Prostate Group Consensus 2009
(Table 1) [13–15]. The following dosimetric indices were
assessed: V10, V30, V50, V70 (defined as the percentage
of organ volume receiving given radiation dose), Dmean,
Dmax and D1cc for rectum and bladder, as well as V50
and D1ccm for femoral heads. A comparison of each pa-
tient was made using a scoring system that compared
D2 %, D98 % and V95 values. The indices for the 20 pa-
tients were averaged to assess the advantages and
Table 1 Organ at risk dose objectives
Organ Dose Volume (in % or in ccm as absolute
volume for femoral heads)













Femoral heads [13] 50Gy <5 %
40Gy ≤1ccm
Abbreviations: a-the dose-volume limit is not defined in the QUANTEC reports
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disadvantages in PTV coverage and OAR sparing of the
various radiation techniques.
Based on the recommendations of the ICRU 83 re-
ports and several clinical studies, specific conformal in-
dices were used to describe the dose distribution [12, 16].
Thus, the homogeneity index (HI) and four conformity
indices (CI; these include the ICRU conformity index
(CIICRU), coverage index (CΔ), coverage index COV
(CΔCOV), and conformation number (CN)) were calcu-
lated (Table 2). These indices refer to the PTV volume,
partial PTV volume covered by 95 % of prescribed iso-
dose (PTVpi), and volume treated by 95 % of prescribed
isodose (TVPI) [16]. The HI characterizes dose homo-
geneity inside the PTV and is calculated using the near
maximum (D2 %), near minimum (D98 %), and the
mean dose (Dmean): D2 %–D98 % / Dmean (optimal at 0)
[12]. The CN provides complementary information about
the irradiation of PTV and healthy tissues, and is calcu-
lated as PTVpi/ PTV x PTVpi/ TVPI; a value of 1 indicates
optimal result [17]. The CIICRU was described in the ICRU
62 report and is defined as the quotient TVPI/ PTV (opti-
mal at 1) [18]. The CΔ quantifies the radiation exposure
of the surrounding healthy tissue and is defined as TVPI-
PTVpi/ PTV (optimal at 0) [19]. The CΔCOV describes the
coverage of the target volume by the prescribed isodose
and is calculated as PTVpi/ PTV; ideal PTV coverage is in-
dicated by a value of 1 [20].
A comparison of monitor units and treatment times
could not be performed because the current imple-
mentation of monitor unit calculation in Eclipse Pro-
ton Planning is based on theoretical ideas and has
not yet been verified by measurements due to a lack
of experimental data (Proton Algorithm Reference
Guide, Eclipse™ August 2013, Varian Medical Systems,
Inc., Palo Alto).
In the statistical analyses, a non-parametric Wilcoxon
signed-rank test was used to assess the differences be-
tween two techniques. The threshold for statistical sig-
nificance was defined as P < .05. All statistical analyses
were performed using the SPSS software (IBM SPSS
Statistics 22.0).
Treatment plans were created separately by three
physicists.
Results
The dosimetric values for PTV and OAR were assessed
from the patient-averaged dose-volume histogram (DVH)
and are presented in detail in Tables 2 and 3. The D98 %
and D2 % did not significantly vary between the tech-
niques. However, the HT showed inferior dose distribution
within the PTV, with the largest interval between D98 %
and D2 % values compared to SW, RA and IMPT. The
IMPT provided significantly superior homogeneity values
compared to HT, SW and RA (Table 2). Comparison of
the four CI, which describe the dose distribution within
the PTV and the healthy tissue, demonstrated HT showed
a tendency toward inferior conformation (Table 2). A
paired comparison analysis showed significantly improved
CN for RA compared to HT (P = .001), SW (P = .005), and
IMPT (P = .001). The IMPT demonstrated superior CN
compared to HT (P = .001). The CIICRU value of 1.20
obtained by HT reflects a larger coverage volume by
the treatment dose than the PTV itself. For RA was
found significantly superior CIICRU in contrast to HT
and IMPT (P = .001), and SW showed superior CIICRU
compared to HT (P = .001) and IMPT (P = .002). The
CΔ revealed that RA was significantly superior to all
other techniques, and that SW was superior to HT and
IMPT (P < .05). IMPT showed significantly better CICOV
values than other modalities (P < .05) (Table 2).
A greater difference in dose distribution between the
techniques was found at the low-to-medium dose
ranges compared to the higher doses (Figs. 1 and 2).
The patient-averaged DVH revealed IMPT had statisti-
cally superior rectum sparing at low-to-higher doses
compared to all other techniques (V10–V70, P = <.05),
with the exception of HT at V70 (Fig. 3, Table 3). Sig-
nificantly lower rectum exposure was provided by HT









Pairs with statistically significant differences
(P = . < 05)/Technique with best result (mean values)
PTV
PTV coverage (%) 98.2 ± 1.4 98.6 ± 0.8 98.3 ± 0.8 99.6 ± 0.2 Pr > HT, Pr > SW, Pr > RA / Pr > SW > RA > HT
D2 % (%) 103.3 ± 0.5 102.5 ± 0.4 102.4 ± 0.3 102.5 ± 0.4 RA > HT, SW > HT, Pr > HT / RA > SW = Pr > HT
D98 % (%) 95.3 ± 1.9 95.5 ± 0.6 95.3 ± 0.6 96.7 ± 0.4 Pr > HT, Pr > SW, Pr > RA / Pr > SW > RA > HT
Homogeneity index, HI 0.08 ± 0.02 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01 Pr > HT, Pr > SW, Pr > RA / Pr > SW = RA > HT
Conformation number, CN 0.81 ± 0.04 0.89 ± 0.02 0.91 ± 0.03 0.88 ± 0.02 SW > HT, RA > HT, RA > SW, RA > Pr, Pr > HT / RA > SW > Pr > HT
ICRU Conformity index, CIICRU 1.20 ± 0.1 1.09 ± 0.03 1.07 ± 0.04 1.13 ± 0.03 SW > HT, SW > Pr, RA > HT, RA > Pr, Pr > HT / RA > SW > Pr > HT
Coverage index, CΔ 0.22 ± 0.1 0.11 ± 0.03 0.08 ± 0.03 0.13 ± 0.03 RA > HT, RA > SW, RA > Pr, SW > HT / RA > SW > Pr > HT
Coverage index COV, CΔCOV 0.98 ± 0.01 0.99 ± 0.01 0.98 ± 0.01 1.00 ± 0.0 Pr > HT, Pr > SW, Pr > RA / Pr > SW > RA = HT
Abbreviations: HT helical tomotherapy; SW Sliding Window; RA Rapid Arc; Pr Protons; SD standard deviation; > dosimetric superiority
Scobioala et al. Radiation Oncology  (2016) 11:128 Page 3 of 8









Pairs with statistically significant differences
(P = . < 05)/Technique with best result (mean values)
Urinary Bladder
V10 (%) 42.0 ± 23.8 39.3 ± 23.3 46.8 ± 23.2 30.2 ± 18.5 Pr > HT, Pr > SW, Pr > RA, SW > HT, SW > RA / Pr > SW > HT > RA
V30 (%) 26.2 ± 18.6 23.5 ± 16.4 27.0 ± 19.1 21.2 ± 14.7 Pr > HT, Pr > SW, Pr > RA, SW > HT, SW > RA / Pr > SW > HT > RA
V50 (%) 16.8 ± 12.5 15.6 ± 11.6 17.0 ± 13.3 15.3 ± 11.5 SW > HT, SW > RA, Pr > RA, Pr > HT / Pr > SW > HT > RA
V70 (%) 6.0 ± 4.9 5.4 ± 4.8 6.4 ± 4.8 5.3 ± 4.7 Pr > SW, Pr > RA, Pr > HT / Pr > SW > HT > RA
Dmean (Gy) 17.4 ± 10.1 15.8 ± 9.6 17.9 ± 10.1 13.3 ± 9.1 Pr > HT, Pr > SW, Pr > RA, SW > HT, SW > RA / Pr > SW > HT > RA
Dmax (Gy) 82.5 ± 2.8 80.0 ± 2.8 80.9 ± 3.1 80.9 ± 1.7 SW > HT, RA > HT, Pr > HT / SW > Pr > RA > HT
D1ccm (Gy) 76.3 ± 8.2 76.2 ± 6.3 76.3 ± 8.1 76.2 ± 6.0 SW > HT, Pr > HT / Pr > SW > RA > HT
Rectum
V10 (%) 59.1 ± 17.9 62.7 ± 16.6 69.0 ± 18.7 24.6 ± 9.2 Pr > HT, Pr > SW, Pr > RA, HT > SW, HT > RA, SW > RA / Pr > HT > SW > RA
V30 (%) 24.8 ± 7.6 32.8 ± 5.7 41.7 ± 11.3 15.7 ± 5.8 Pr > HT, Pr > SW, Pr > RA, HT > SW, HT > RA, SW > RA / Pr > HT > SW > RA
V50 (%) 12.8 ± 4.0 17.3 ± 2.5 23.5 ± 7.5 9.3 ± 3.8 Pr > HT, Pr > SW, Pr > RA, HT > SW, HT > RA, SW > RA / Pr > HT > SW > RA
V70 (%) 1.1 ± 0.7 1.5 ± 0.8 3.4 ± 1.8 1.0 ± 0.8 Pr > RA, Pr > SW, HT > SW, HT > RA, SW > RA / Pr > HT > SW > RA
Dmean (Gy) 17.3 ± 3.9 20.3 ± 3.4 24.5 ± 5.3 9.0 ± 3.4 Pr > HT, Pr > SW, Pr > RA, HT > SW, HT > RA, SW > RA / Pr > HT > SW > RA
Dmax (Gy) 78.3 ± 1.8 75.9 ± 1.2 77.3 ± 1.5 76.4 ± 2.2 Pr > HT, Pr > RA, SW > HT, SW > RA, SW > Pr / SW > Pr > RA > HT
D1ccm (Gy) 67.5 ± 4.1 68.9 ± 2.4 71.5 ± 2.5 65.9 ± 4.2 HT > SW, HT > RA, SW > RA, Pr > HT, Pr > SW, Pr > RA / Pr > HT > SW > RA
Femoral head, right
D1ccm (Gy) 18.0 ± 2.9 32.0 ± 6.2 28.1 ± 5.3 35.2 ± 3.9 HT > SW, HT > RA, HT > Pr, RA > SW, RA > Pr / HT > RA > SW > Pr
Femoral head, left
D1ccm (Gy) 18.1 ± 2.9 31.9 ± 5.1 26.6 ± 5.0 35.5 ± 2.5 HT > SW, HT > RA, HT > Pr, RA > Pr, RA > SW / HT > RA > SW > Pr
Abbreviations: HT helical tomotherapy; SW Sliding Window; RA Rapid Arc; Pr Protons; PTV planning target volume; SD standard deviation; Dx (Gy) dose (Gy)




Fig. 1 Treatment plans for tomotherapy (HT), Sliding Window (SW), Rapid Arc (RA), and protons (IMPT). Representative dose distribution with V10
(yellow), V30 (green), V50 (blue), and V70 (orange) isodoses. The prostate is delineated in red, rectum in brown, urinary bladder in yellow
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compared to SW and RA at low-to-higher doses (V10–
V70, P < .05) (Fig. 3, Table 3). A statistical difference in
Dmean values was found in all tested pairs, with lower
absolute values for protons and a maximum of absolute
values for RA. Lowest Dmax value was achieved by
SW, and D1ccm values revealed protons produced the
lowest radiation exposure and RA produced the great-
est coverage (Table 3).
The whole urinary bladder also experienced the best
shielding using IMPT at lower-to-higher doses (V10–
V70, P < .05) (Fig. 3, Table 3). SW demonstrated signifi-
cantly lower bladder exposure in a wide dose spectrum
than HT and RA (V10–V50, P < .05) (Fig. 3, Table 3).
Dmean values were significantly different between all
tested pairs, except for HT/RA, with lower absolute
values for IMPT and higher absolute values for RA. Sig-
nificantly lower Dmax values were gained for SW.
D1ccm values revealed nearly the same bladder exposure
for all techniques (Table 3).
D1ccm values indicated femoral heads experienced the
highest exposure from protons and superior sparing
from HT (Table 3). V50 revealed femoral heads received
very small coverage volume (<1 %) for all techniques.
Discussion
This study performed a statistical dosimetric comparison
between different IMRT techniques using conventional
fractionation to treat low-risk prostate cancer. IMRT
was found to provide a conformal dose distribution,
allowing dose escalation in the prostate and inferior
OAR toxicity compared to 3-D conformal radiotherapy
(3-D CRT) [21–24]. A dosimetric comparison between
different IMRT techniques has already been performed
in several series of studies [1–4, 25–32]. Tsai et al. found
that HT provided superior conformity and OAR sparing
compared to VMAT and static IMRT [2]. Hermann et al.
demonstrated comparable homogeneity, CN values and
OAR dosimetric values between VMAT, SS and SW
[26]. The dosimetric comparison between static and ro-
tational IMRT in this trial revealed superior rectum
sparing by HT and superior bladder sparing by SW at
low-to-higher doses (Table 3, Fig. 3). However, no accen-
tuated priority for rectum sparing in HT plans or for
bladder sparing in SW plans was made by the plans’ as-
sessment. In our opinion, the Tomo Planning System is
more sensitive to dose constraints than the Eclipse plan-
ning system. This increased sensitivity can result in
greater rectum sparing in HT plans while using the same
dose objectives in the Eclipse planning system for SW
and RA. In addition, the high sensitivity of the Tomo
Planning System can result in larger SD values for
homogeneity and the conformity indices in HT plans
compared to other IMRT techniques, as shown in
Table 2. A higher radiation exposure for OAR at low
doses was found for RA compared to HT and SW. Des-
pite the use of two incomplete arcs intended to protect
the rectum, RA demonstrated greater rectum exposure
in a wide dose spectrum (Table 3). However, most of the
conformity values were statistically superior for RA com-
pared to SW and HT. Thus, assuming same dose objec-
tives for treatment planning, differences in dose
distribution within PTV and OAR can be explained both
by impact of radiation technique itself and by use of dif-
ferent dose calculation algorithms.
Superior sparing of OAR by protons is expected due
to extremely steep dose gradients outside of the Bragg




Fig. 2 Patient-averaged dose-volume histograms. Dose-volume
relationship of the planning target volume (a), rectal wall (b), and
bladder wall (c) in the treatment plans of various IMRT techniques
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prostate carcinoma, protons provided improved rectum
sparing at 10–80Gy and bladder sparing at 10–35Gy
compared to the IMRT techniques [5]. On the contrary,
a comparable sparing of rectum, bladder and femoral
heads for IMPT and VMAT techniques was observed by
Georg et al. [6]. In agreement with the results found by
Schwarz et al., IMPT revealed similar homogeneity
values and significantly inferior conformity values com-
pared to HT. Rectum exposure for both techniques
above 65Gy was equivalent, and superior sparing of
bladder and penile bulb was obtained for protons in a
wide dose spectrum [7]. A recent SEER-Medicare based
study observed a lower rate of gastrointestinal toxicity
by IMRT-treated patients compared to proton-treated
patients, and similar outcomes were observed for urin-
ary toxicity and erectile dysfunction [9]. Based on nor-
mal tissue complication probability (NTCP) estimates,
Schwarz et al. demonstrated very similar probabilities
of late gastrointestinal complications for HT and IMPT
[7]. Thus, the current data do not permit a definitive
conclusion about the dosimetric superiority and ther-
apy tolerance of protons compared to IMRT. In this
study, IMPT showed an improved homogeneity value
compared to the other techniques, and lower conform-
ity values compared to SW and RA (Table 2), although
the planning software did not allow for a robust
optimization of the proton therapy. In accordance with
the findings of Vargas et al., the protons demonstrated
statistically superior rectum and bladder sparing at
low-to-higher doses (Table 3, Fig. 3). In the case of
highly curative low-risk prostate carcinoma, it is critical
both to perform homogeneous prostate coverage in
order to achieve a long-term local tumor control, and
to minimize the risk of chronic toxicities and secondary
malignances. The steep dose gradient to the rectum
and bladder, even at the lowest doses, leads to the as-
sumption of decreased risk of secondary malignancy
after proton treatment. However, the clinical relevance
of the higher exposure of the femoral heads through
the opposing right and left lateral beams used by pro-
tons is unknown. Thus, the incidence of late toxicity,
including secondary malignancy, after proton treatment
should be further evaluated in long-term trials.
The dose objectives for the rectum and urinary blad-
der met the criteria laid out by the QUANTEC reports
[14, 15]. Current dose constraints are primarily gener-
ated from 3-D CRT datasets [22]. The advanced IMRT
techniques, including protons, all provide highly con-
formal dose distribution, performing superior OAR spar-
ing than 3-D CRT. For this reason, dose objectives
should be derived from the datasets of these advanced
radiotherapy technologies.
For each radiation technique, a corresponding plan-
ning system is used to determinate dose calculation al-
gorithms. Moreover, radiation plans can be optimized by
individual modification of dose objectives for each treat-
ment case. These arguments can diminish the relevance
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Sliding Window vs. Rapid Arc
Fig. 3 Pair-wise statistical dosimetric comparison between radiation techniques. The differences in OAR sparing are shown at dose ranges V10–V70,
Dmean and Dmax for rectum and urinary bladder, and D1ccm for femoral heads. The urinary bladder is indicated in yellow, rectum in brown, femoral
heads in green
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objectives in radiation planning. Thus, the selection cri-
teria for dosimetric comparison of treatment plans
should be further optimized.
De Meerleer et al. demonstrated that static IMRT
plans had a superior ratio of tumor control probability
(TCP)/normal tissue complication probabilities (NTCP)
compared to 3-D CRT plans. As a result, IMRT tech-
niques provide improved tumor control without a cor-
responding increase in radiation toxicities [33]. The
clinical relevance of dosimetric differences between
various advanced IMRT techniques should be further
analyzed in relation to NTCP parameters, including
risk of secondary malignancy, as already described by
Hall in several reviews [34, 35].
And finally, late-responding organs that have a low
α/β ratio such as the prostate are more sensitive to
high fraction doses [36, 37]. Several retrospective stud-
ies demonstrated the dosimetric feasibility, clinical
outcomes, and local tumor control of hypofractionated
radiotherapy in the treatment of localized prostate car-
cinoma [38–41]. Our ongoing research will focus on
evaluating dose objectives for various advanced radi-
ation techniques, including the Cyber Knife technique,
in order to simultaneously provide homogeneous pros-
tate coverage and conformal dose distribution through
the delivery of a large fraction dose.
Conclusion
The major findings to emerge from this study are as fol-
lows: (i) All techniques revealed a homogeneous and
high conformal dose distribution with more explicit dif-
ferences at the low-to-medium dose ranges. At the dose
above 50Gy all techniques demonstrated a steep dose
gradient outside the PTV, implying a similar frequency
and severity of acute toxicities. (ii) When using the same
dose objectives during planning, IMPT revealed superior
rectum and bladder sparing in a wide dose spectrum.
This trend was more relevant at the low-to-medium
doses. The superior OAR sparing by IMPT was con-
cordant with results of Vargas et al, while did not
match the results of Georg et al [5, 6]. In contrast to
findings of Schwarz et al., IMPT revealed conformity
values comparable to SW and RA techniques and even
superior to HT [7]. (iii) While the slight advantage in
bladder sparing by SW can be explained by the use of
different dose calculation algorithms during the treat-
ment plan optimization process, the highly significant
superior rectum sparring by HT can only be partially
explained by the algorithm and is assumed to be a re-
sult of the HT treatment technique. Of course, the radi-
ation plans can be further optimized by individual
modification of dose objectives in dependence of treat-
ment plan strategy.
Additional file
Additional file 1: Support strukture and dose objectives used for OAR.
(DOCX 15 kb)
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